Skip to main content

Table 3 Genotype and haplotype association analysis in ILVBL gene with the risk of AERD

From: Association analysis of ILVBL gene polymorphisms with aspirin-exacerbated respiratory disease in asthma

Locus Diag Genotype Codominant. Dominant. Recessive
RR CR CC Total OR [95% CI] P* Pcorr ** OR [95% CI] P* Pcorr ** OR [95% CI] P* Pcorr **
rs2074267 AERD 20 (14.2%) 61 (43.3%) 60 (42.6%) 141 (100%) 0.79 [0.61–1.04] 0.087 0.799 0.67 [0.47–0.96] 0.030 0.273 0.91 [0.55–1.52] 0.729 1.000
ATA 153 (15.4%) 517 (52.0%) 325 (32.7%) 995 (100%)
rs4141356 AERD 31 (22.0%) 64 (45.4%) 46 (32.6%) 141 (100%) 1.33 [1.04–1.72] 0.026 0.235 1.3 [0.89–1.89] 0.174 1.000 1.73 [1.12–2.69] 0.014 0.131
ATA 140 (14.1%) 473 (47.5%) 382 (38.4%) 995 (100%)
rs718100 AERD 30 (21.3%) 61 (43.3%) 50 (35.5%) 141 (100%) 1.43 [1.11–1.85] 0.006 0.050 1.38 [0.95–1.99] 0.089 0.819 2.04 [1.30–3.20] 0.002 0.017
ATA 116 (11.7%) 452 (45.4%) 427 (42.9%) 995 (100%)
rs2074265 AERD 30 (21.3%) 62 (44.0%) 49 (34.8%) 141 (100%) 1.43 [1.11–1.84] 0.006 0.055 1.39 [0.96–2.01] 0.081 0.745 1.98 [1.27–3.11] 0.003 0.026
ATA 119 (12.0%) 454 (45.6%) 422 (42.4%) 995 (100%)
rs2240299 AERD 7 (5.0%) 54 (38.3%) 80 (56.7%) 141 (100%) 0.59 [0.45–0.79] 3.65 × 10−4 0.003 0.57 [0.4–0.82] 0.002 0.020 0.34 [0.16–0.75] 0.007 0.068
ATA 131 (13.2%) 438 (44.1%) 425 (42.8%) 994 (100%)
rs7507755 AERD 7 (5.0%) 54 (38.3%) 80 (56.7%) 141 (100%) 0.59 [0.45–0.79] 3.78 × 10−4 0.003 0.57 [0.4–0.82] 0.002 0.021 0.34 [0.16–0.75] 0.008 0.069
ATA 131 (13.2%) 438 (44.0%) 426 (42.8%) 995 (100%)
rs1468198 AERD 22 (15.6%) 68 (48.2%) 51 (36.2%) 141 (100%) 0.60 [0.47–0.78] 9.53 × 10−4 0.001 0.47 [0.29–0.75] 0.002 0.016 0.53 [0.37–0.78] 0.001 0.010
ATA 279 (28.1%) 483 (48.7%) 230 (23.2%) 992 (100%)
rs2074261 AERD 22 (15.6%) 63 (44.7%) 56 (39.7%) 141 (100%) 0.62 [0.48–0.8] 2.30 × 10−4 0.002 0.54 [0.38–0.78] 0.001 0.010 0.51 [0.31–0.82] 0.005 0.048
ATA 263 (26.5%) 469 (47.2%) 262 (26.4%) 994 (100%)
rs13301 AERD 22 (15.6%) 65 (46.1%) 54 (38.3%) 141 (100%) 0.64 [0.5–0.82] 4.20 × 10−4 0.004 0.57 [0.39–0.83] 0.003 0.027 0.5 [0.31–0.81] 0.005 0.043
ATA 265 (26.7%) 468 (47.1%) 261 (26.3%) 994 (100%)
  Haplotype  
+/+ −/+ −/− Total
BL1ht1 AERD 16 (11.3%) 57 (40.4%) 68 (48.2%) 141 (100%) 0.78 [0.6–1.03] 0.084 0.672 0.67 [0.47–0.96] 0.028 0.226 0.94 [0.54–1.64] 0.829 1.000
ATA 119 (12.0%) 498 (50.2%) 376 (37.9%) 993 (100%)
BL1ht3 AERD 9 (6.4%) 44 (31.2%) 88 (62.4%) 141 (100%) 0.86 [0.64–1.17] 0.343 1.000 0.79 [0.55–1.14] 0.213 1.000 1.06 [0.51–2.21] 0.873 1.000
ATA 57 (5.7%) 367 (37.0%) 569 (57.3%) 993 (100%)
BL1ht4 AERD 0 (0.0%) 9 (6.4%) 132 (93.6%) 141 (100%) 0.86 [0.42–1.76] 0.688 1.000 0.87 [0.42–1.79] 0.709 1.000 inf 0.999 1.000
ATA 1 (0.1%) 71 (7.2%) 921 (92.7%) 993 (100%)
BL2ht3 AERD 3 (2.1%) 32 (22.7%) 106 (75.2%) 141 (100%) 0.9 [0.62–1.3] 0.565 1.000 0.86 [0.57–1.3] 0.486 1.000 1.12 [0.33–3.85] 0.856 1.000
ATA 19 (1.9%) 253 (25.4%) 723 (72.7%) 995 (100%)
BL2ht4 AERD 0 (0%) 6 (4.3%) 135 (95.7%) 141 (100%) 0.77 [0.33–1.8] 0.541 1.000 0.77 [0.33–1.84] 0.560 1.000 inf 0.999 1.000
ATA 1 (0.1%) 54 (5.4%) 940 (94.5%) 995 (100%)
  1. R rare allele, C common allele, ATA aspirin tolerant asthmatics, AERD aspirin-exacerbated respiratory disease, OR odd ratio, CI confidence interval
  2. *P values were obtained using logistic regression analysis controlling age of onset, smoking status and BMI as covariates
  3. **Corrected P values for multiple comparison using SNPSpD